Clinical trials
Every registered trial of GHK-Cu (Copper Peptide)
2 studies, 1 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on GHK-Cu (Copper Peptide) has been registered.
- 2 registered studies in total.
- 1 is still enrolling people, so this is active research, not just history.
What kind of research
- 2 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 87 people took part in those.
How far along it is
- 1 trial has reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- None have published results in the medical literature yet, so the findings are not yet open to outside scrutiny.
- The research spans 2 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 2 of 2 trials for GHK-Cu (Copper Peptide).
Topical GHK-Cu Gel for Acute Skin Wound Healing
Hudson Biotech
Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds)
Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.
Austin Institute for Clinical Research
Cutis Laxa Facialis · Xeroderma
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when GHK-Cu (Copper Peptide) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.